With five observations
Alembic Pharmaceuticals announced that United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' New Injectable Facility (F-3) located at Karkhadi from 29 January 2021 to 5 February 2021. This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with 5 observations.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
